Aspire Biopharma Holdings (ASBP) Non-Current Debt (2023 - 2025)

Aspire Biopharma Holdings (ASBP) has reported Non-Current Debt for 3 consecutive years, with $1.5 million the latest figure, recorded in Q4 2025.

• On a quarterly basis, Non-Current Debt rose 200.0% year-over-year to $1.5 million in Q4 2025; TTM through Dec 2025 was $1.5 million, a 200.0% increase from a year earlier, with the FY2025 full-year figure at $1.5 million, up 200.0% from the prior year.
• Non-Current Debt was $1.5 million for Q4 2025 at Aspire Biopharma Holdings, up from $500000.0 in the prior quarter.
• Over five years, Non-Current Debt peaked at $1.5 million in Q4 2025 and troughed at $360636.0 in Q4 2023.
• A 3-year average of $715159.0 and a median of $500000.0 in 2024 frame the typical range for Non-Current Debt.
• Across the five-year window, Non-Current Debt soared 38.64% in 2024 and soared 200.0% in 2025, its largest moves.
• Over 3 years, Non-Current Debt stood at $360636.0 in 2023, then jumped by 38.64% to $500000.0 in 2024, then soared by 200.0% to $1.5 million in 2025.
• The last three Non-Current Debt figures came in at $1.5 million (Q4 2025), $500000.0 (Q4 2024), and $500000.0 (Q3 2024), per Business Quant data.